Images

Filter by

Figure 2 Pathophysiological Progression of Endothelial Dysfunction and Its Impact on Heart Failure
Figure 2: Pathophysiological Progression of Endothelial Dysfunction and Its Impact on Heart Failure
Table 1 Consequences of Common Cardiovascular Risk Factors on Endothelial Function
Table 1: Consequences of Common Cardiovascular Risk Factors on Endothelial Function
Figure 1 Impact of Cardiovascular Risk Factors on Endothelial Cells and Vascular Function
Figure 1: Impact of Cardiovascular Risk Factors on Endothelial Cells and Vascular Function
Table 3 Future and Ongoing Clinical Trials Investigating Aldosterone Synthase Inhibitors
Table 3: Future and Ongoing Clinical Trials Investigating Aldosterone Synthase Inhibitors
Table 2 Cont
Table 2: Cont.
Table 2 Clinical Trial Data for Current Aldosterone Synthase Inhibitors in Development
Table 2: Clinical Trial Data for Current Aldosterone Synthase Inhibitors in Development
Figure 3 Mechanistic Overview of the Aldosterone Escape Phenomenon
Figure 3: Mechanistic Overview of the Aldosterone Escape Phenomenon
Table 1 Comparative Overview of Steroidal Mineralocorticoid Receptor Antagonists Nonsteroidal Mineralocorticoid Receptor Antagonists and Aldosterone Synthase Inhibitors
Table 1: Comparative Overview of Steroidal Mineralocorticoid Receptor Antagonists, Nonsteroidal Mineralocorticoid Receptor Antagonists and Aldosterone Synthase Inhibitors
Figure 2 The Pathological Consequences of Excess Aldosterone and Potential Therapeutic Applications of Aldosterone Synthase Inhibitors
Figure 2: The Pathological Consequences of Excess Aldosterone and Potential Therapeutic Applications of Aldosterone Synthase Inhibitors
Figure 1 Overview of the Adrenal Gland Structure Steroidogenesis Pathways and the Role of Aldosterone Synthase Inhibitors in Modulating Aldosterone Production
Figure 1: Overview of the Adrenal Gland Structure, Steroidogenesis Pathways and the Role of Aldosterone Synthase Inhibitors in Modulating Aldosterone Production
Table 1 Overview of Randomised Clinical Trials Analysing the Effectiveness of Glucagon‑like Peptide 1 Receptor Agonists With Specific Focus on Heart Failure Outcomes
Table 1: Overview of Randomised Clinical Trials Analysing the Effectiveness of Glucagon‑like Peptide-1 Receptor Agonists With Specific Focus on Heart Failure Outcomes
Figure 1 Timeline of Randomised Clinical Trials of Glucagon like Peptide 1 Receptor Agonists
Figure 1: Timeline of Randomised Clinical Trials of Glucagon-like Peptide-1 Receptor Agonists